We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Saturday
May 16
17:00 - 18:00
T2
Urological cancers 1
Martin Dolezel, Czech Republic;
Raouia Ben Amor, Tunisia
Mini-Orals
Clinical
17:00 - 18:00
Adjuvant radiotherapy following radical cystectomy in muscle-invasive bladder cancer: a systematic review and meta-analysis of randomised trials
Chia Ching Lee, Singapore
-3185
17:00 - 18:00
Lymphopenia after whole-pelvis Radiotherapy in prostate Cancer patients is a major predictor of late patient-reported Intestinal Toxicity
Claudio Fiorino, Italy
-2184
17:00 - 18:00
No toxicity benefit with proton versus photon therapy for prostate cancer: two-year results from the ProtoChoice-P prospective matched-pair study.
Tobias Hölscher, Germany
-2351
17:00 - 18:00
Efficacy and Toxicity of Hypofractionated and Dose-Boosted Radiotherapy for Localised Prostate Cancer: A Systematic Review and Meta-Analysis
Marcin Miszczyk, Poland
-3452
17:00 - 18:00
Safety Profile of Darolutamide Combined With ADT and Radiotherapy in Node-Positive Prostate Cancer: Analysis From the GETUG-P17 ALADDIN Trial
Jean-Emmanuel Bibault, France
-51
17:00 - 18:00
Daily Adaptive MR-Guided RT Improves Urinary Symptoms in Prostate Cancer: A Prospective International Cohort Study (NCT04075305)
Faye Raaijmakers, The Netherlands
-3788
17:00 - 18:00
Two-fractionated stereotactic MR-guided adaptive radiotherapy for patients with prostate cancer: a nationwide, multi-institutional prospective study
Tairo Kashihara, Japan
-481
17:00 - 18:00
Long-Term Follow Up of the HypoFocal Phase II Trial: PSMA-PET- /MRI-based Focal Dose Escalated Radiotherapy for Intermediate/High-Risk Prostate Cancer
Simon KB Spohn, Germany
-4350